APTN — ADAPTIN BIO, INC.

—
OTC · Health Care · Biotechnology · CIK 1938571 ·
Last close
$6.27
Market Cap
—
52W High
$6.27
52W Low
$6.27
ADV30
100
Next earnings
—
Adaptin Bio, Inc. develops biotechnology products for the treatment of cancer and other diseases. The company develops bispecific antibody-based therapies using its BRiTE Platform technology. Its BRiTE Platform uses fully human bispecific antibodies to redirect patients' T cells to recognize and destroy tumor cells and facilitate the delivery of T cell-targeting agents across the blood-brain barrier. The company's product pipeline includes APTN-101, an EGFRvIII x CD3 bispecific T cell engager designed to redirect T cells against tumors expressing a mutated form of epidermal growth factor receptor (EGFR), including glioblastoma, breast cancer, and lung cancer. The BRiTE Platform is focused on enabling access to the brain for T cell-targeting agents and supporting immunotherapeutic approaches for malignant glioma and other cancers. The company's technology platform is designed to utilize the human immune system to recognize, target, destroy, or deliver therapeutics to specific cells, including cancer cells. The company was formerly known as Centaur Bio Inc. Adaptin Bio, Inc. was incorporated in 2021 and is based in Charlotte, North Carolina.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 0 -1,200,616 -1,205,312 981,452 670,488 2,646,802
Mar 2026 0 0 -1,144,153 -1,146,096 706,117 301,309 2,481,688
Sep 2025 0 0 -1,675,612 -1,675,612 979,474 579,089 1,860,552
Jun 2025 0 0 -1,520,855 -1,520,855 1,662,635 1,351,519 1,188,226

Annual Trend (SEC EDGAR, last 3y)

Revenues vs Net Income (last 3y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -5,414,943 -5,167,569 619,159 2,108,555 -1,489,396 —
Dec 2024 0 -155,374 -161,160 12,619 286,676 -274,057 —
Dec 2023 — — -85,593 380 113,277 -112,897 —

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-5,395,038
OpCashFlow TTM
—
Assets (Latest)
$981,452
Forward EPS
—

Peers — same industry

TickerNameMarket CapLastDaily %
AMGN AMGEN INC $247.70B $457.93 —
GILD GILEAD SCIENCES, INC. $211.18B $170.26 —
MRNA Moderna, Inc. $82.56B $206.80 —
ARGX ARGENX SE $58.92B $947.52 —
BIIB BIOGEN INC. $37.07B $250.79 —

News headlines (Yahoo Finance, 1h cache)

Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
2026-09-18 12:35 · Yahoo
Life Sciences Virtual Investor Forum Agenda Announced
2026-09-14 12:35 · Yahoo
Adaptin Bio Announces Opening of Enrollment in a Phase 1 Clinical Trial Evaluating Treatment of Malignant Brain Tumors with APTN-101
2026-08-20 20:02 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.